The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
2024

177Lu-PSMA-617 Radioligand Therapy for Prostate Cancer

Sample size: 831 publication 10 minutes Evidence: high

Author Information

Author(s): Konopnicki Alexander, Zaliznyak Michael, Roy Mathews, Jana Bagi

Primary Institution: University of Texas Medical Branch

Hypothesis

Can 177Lu-PSMA-617 improve treatment outcomes in various stages of prostate cancer?

Conclusion

177Lu-PSMA-617 has shown significant efficacy in treating metastatic castration-resistant prostate cancer and is being explored in earlier stages of the disease.

Supporting Evidence

  • 177Lu-PSMA-617 gained FDA approval for treating progressive castration-resistant prostate cancer.
  • The VISION trial showed significant improvement in patient outcomes with 177Lu-PSMA-617.
  • Patients treated with 177Lu-PSMA-617 had a median radiographic progression-free survival of 8.7 months.

Takeaway

This study looks at a special treatment for prostate cancer that uses a radioactive substance to target cancer cells, helping patients live longer and feel better.

Methodology

This review summarizes key phase III randomized controlled trials and ongoing studies related to 177Lu-PSMA-617 in prostate cancer.

Potential Biases

Potential publication bias in the studies reviewed.

Limitations

The review does not provide new experimental data and relies on existing literature.

Participant Demographics

The studies included male patients with metastatic castration-resistant prostate cancer.

Statistical Information

P-Value

p<0.0001

Confidence Interval

95% CI 0.29 to 0.57

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1007/s12672-024-01680-z

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication